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HEMOSTASIS, THROMBOSIS, AND VASCULAR BIOLOGY
Activated protein C–cleaved protease activated receptor-1 is retained on the
endothelial cell surface even in the presence of thrombin
Reto A. Schuepbach,1 Clemens Feistritzer,1 Lawrence F. Brass,2 and Matthias Riewald1
1Department of Immunology, Scripps Research Institute, La Jolla, CA; and 2University of Pennsylvania, Philadelphia
Activated protein C (APC) signals in endo-
thelial cells ex vivo through protease acti-
vated receptor-1 (PAR1). However, it is
controversial whether PAR1 can mediate
APC’s protective effects in sepsis be-
cause the inflammatory response results
in thrombin generation and thrombin pro-
teolytically activates PAR1 much more
efficiently than APC. Here we show that
APC can induce powerful barrier protec-
tive responses in an endothelial cell
monolayer in the presence of thrombin.
Using cell surface immunoassays with
conformation sensitive monoclonal anti-
PAR1 antibodies we analyzed cleavage of
endogenous PAR1 on the endothelial cell
surface by APC in the absence and pres-
ence of thrombin. Incubation with APC
caused efficient PAR1 cleavage and upon
coincubation with thrombin APC sup-
ported additional PAR1 cleavage.
Thrombin-cleaved PAR1 rapidly disap-
peared from the cell surface whereas,
unexpectedly, the APC-cleaved PAR1 re-
mained and could be detected on the cell
surface, even when thrombin at concen-
trations of up to 1 nM was also present.
Our findings demonstrate for the first
time directly that APC can generate a
distinct PAR1 population on endothelial
cells in the presence of thrombin. The
data suggest that different trafficking of
activated PAR1 might explain how PAR1
signaling by APC can be relevant when
thrombin is present. (Blood. 2008;111:
2667-2673)
© 2008 by The American Society of Hematology
Introduction
Recombinant human activated protein C (APC) has powerful
protective effects in systemic inflammation that led to its approval
to treat patients with severe sepsis.1 Protein C (PC) is physiologi-
cally activated on the endothelial cell surface by the key procoagu-
lant enzyme thrombin and APC down-regulates thrombin forma-
tion in a negative feedback loop.2 However, this anticoagulant
effect of APC is unlikely to explain its benefit in systemic
inflammation because other anticoagulants with comparable effect
do not improve survival in septic patients3,4 or in animal models.5
More recently, APC signaling through protease activated
receptor-1 (PAR1) emerged as an alternative mechanism for APC’s
beneficial effects.6,7 In cultured endothelial cells PAR1 mediates
protective effects of APC on gene expression,6,8 survival,9,10 and
barrier integrity.11 PAR1 has also been implicated in mouse models
analyzing neuroprotective effects of APC in vivo.9,12,13 PAR1 is a
7-transmembrane G-protein–coupled receptor that is enzymatically
cleaved after Arg41 to expose a new extracellular N-terminus that
acts as a tethered activating ligand.14 PAR1 is the prototypical
thrombin receptor and thrombin cleaves and activates PAR1 with
high efficiency because it directly binds to PAR1 in an orientation
that favors cleavage.15 In contrast, APC needs to be recruited to a
coreceptor, the endothelial protein C receptor (EPCR), to induce
PAR1-dependent signaling6 but APC remains less efficient than
thrombin.16 Systemic inflammation leads to generation of thrombin
and in view of the relatively low efficiency of PAR1 activation by
APC it has been argued that a role of APC-PAR1 signaling in
sepsis is unlikely.16,17
Here we demonstrate that APC can mediate significant PAR1
cleavage even in the presence of thrombin. In contrast to thrombin-
cleaved PAR1, the APC-cleaved PAR1 accumulates on the endothe-
lial cell surface. The findings support the concept that PAR1 can
mediate protective APC signaling in conditions where thrombin is
also present.
Methods
Reagents and assays
Human thrombin was as described.6,18 Human plasma–derived APC and PC
were from Haematologic Technologies (Essex Junction, VT). Recombinant
human wild-type APC and mutant APC S360A were a gift from Dr John
Griffin (Scripps Research Institute, La Jolla, CA).19 All experiments
involving stimulation with APC included hirudin (Calbiochem, La Jolla,
CA) unless indicated otherwise or if cells were coincubated with APC and
thrombin. Control experiments demonstrated that hirudin alone had no
effect in any of our assays. Brefeldin A was from Calbiochem. Monoclonal
anti-PAR1 ATAP2, WEDE15, and SPAN11 were as described.20,21 Monoclo-
nal rat anti-EPCR RCR-92 (nonblocking) and RCR-252 (blocking) were
provided by Dr Kenji Fukudome (Saga Medical School, Saga, Japan) and
were used at 25 g/mL.22 Amidolytic assays for APC activity were as
described previously.23
Cell culture, permeability assay, and surface immunoassays
EA.hy926 cells24 and primary human umbilical vein endothelial cells
(HUVEC; Cascade Biologics, Portland, OR) were cultivated and macromo-
lecular monolayer permeability was analyzed in a dual chamber system
using Evans blue-labeled bovine serum albumin (BSA) as described
previously.11 For cell-surface enzyme linked immunoassays (ELISA), the
cells were fixed with 2% paraformaldehyde, blocked with 1% BSA and
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probed with anti-PAR1 antibodies at 0.5 g/mL for 30 minutes. A
horseradish peroxidase (HRP)–coupled goat anti-mouse antibody and
tetrametylbenzidine were used for spectrophotometric quantification of
anti-PAR1 binding. To facilitate the comparison of different experiments
the quantification of antibody binding was normalized. Specific blocking
peptides TFLLRNPNDK (for ATAP2), KYEPFWEDEEKNES (for
WEDE15), and NATLDPRSFFLR (for SPAN11) were custom made
(Invitrogen, Carlsbad, CA) and all peptides completely blocked the
respective specific anti-PAR1 staining. Residual unspecific staining was
found to be unaffected by agonists and was subtracted to correct for
background (0% staining). In all experiments nonagonist-treated cells were
included and PAR1 staining in these cells was defined as 100%. The shown
data were generated using EA.hy926 cells and results were confirmed in
HUVECs. For immunofluorescence microscopy EA.hy926 cells were
grown, fixed, and stained on glass cover slides using identical conditions as
for ELISA. Alexa Fluor 488-coupled goat antimouse (Invitrogen) was used
as the secondary antibody. The cover slides were extensively washed,
mounted (Gelmount; Sigma-Aldrich, St Louis, MO), and immediately
analyzed using an Olympus BX60 fluorescence microscope (Olympus,
San Diego, CA).
Biotinylation of cell-surface proteins and Western blotting
After agonist incubation, proteases were quenched, EA.hy926 cells were
washed twice on ice and kept at 4°C for all subsequent steps. Cell-surface
proteins were biotinylated (0.2 mg/mL Sulfo-NHS-SS-biotin for 30 min-
utes; Pierce, Rockford, IL) before extraction in RIPA buffer supplemented
with Complete Protease Inhibitor Cocktail (Roche, Indianapolis, IN),
20 M bestatin, and 0.1 mg/mL phenylmethylsulfonyl fluoride. Biotinyl-
ated proteins were collected using streptavidin agarose (Invitrogen).
Proteins were analyzed by sodium dodecyl sulfate polyacrylamide gel
electrophoresis (SDS-PAGE) under reducing conditions, transferred to
Immobilon-P-membranes (Millipore, Bedford, MA), blocked with dry
milk, and probed with WEDE15 or ATAP2 followed by HRP-coupled goat
antimouse and visualization using the Femto detection system (Pierce). In
blots showing non–cell-surface proteins loading was assessed using anti–-
actin (Sigma-Aldrich) followed by HRP-coupled goat antirabbit. Optical
density of immunoreactive bands was assessed using Scion Image Alpha
4.0.3.2 software (Frederick, MD).
Statistical analysis
Data analysis was performed using the NCSS Statistical & Power Analysis
or SigmaStat 3.5 (Systat Software, San Jose, CA) software. A 2-sample
2-tailed homoscedastic t test was used to calculate the indicated P values.
Results
APC can induce endothelial barrier protective signaling in the
presence of thrombin
Enhancement of endothelial barrier integrity is a sensitive readout
for PAR1-dependent signaling by exogenous and endogenously
generated APC.11,23 To test if APC-PAR1 signaling still occurs
when thrombin is present at concentrations that are expected to lead
to rapid cleavage of the available PAR1, we determined whether
locally generated APC can still mediate protective effects in the
presence of 1 nM thrombin. Neither thrombin alone nor PC
zymogen affected permeability of a monolayer of endothelial cells
in a dual chamber system after 3 hours of incubation. However,
when the cells were coincubated with thrombin and PC, the
generated APC significantly enhanced the barrier function (Figure
1A). We next studied the effect of increasing thrombin concentra-
tions on APC’s barrier enhancing effects. To only vary the thrombin
but not the APC concentration, APC was exogenously added in
these experiments, although exogenous APC is less efficient than
endogenously generated APC. Again APC enhanced the barrier
integrity despite the presence of up to low-nanomolar thrombin
concentrations (Figure 1B). These data indicate that exogenous and
endogenously generated APC still mediate barrier protective ef-
fects even if thrombin is also present. The possibility that thrombin
becomes inhibited or sequestered, allowing APC to induce protec-
tive effects through newly externalized PAR1,25 was ruled out in
control experiments that demonstrated that thrombin’s proteolytic
activity in the cell medium was stable under our experimental
conditions (not shown).
Quantification of endogenous PAR1 on the endothelial cell
surface by immunoassays
Because it is not possible to directly prove that APC’s barrier
enhancing effects in the presence of thrombin-PAR1 signaling still
depend on PAR1 cleavage, we established assays to assess cleavage
of endogenous PAR1 by APC and thrombin alone and in combina-
tion. A tagged PAR1 construct has been used to measure PAR1
cleavage in a previous report.16 However, such transfected PAR1
constructs were later shown to have decreased susceptibility
toward cleavage by APC as compared with endogenously ex-
pressed PAR1, most likely because of relative unavailability of
EPCR.26 We therefore established a quantitative cell-surface ELISA
to analyze how cleavage and/or conformation of endogenous
endothelial cell PAR1 are affected. Control experiments using
Figure 2. Quantification of cell surface–exposed PAR1. Confluent EA.hy926 cells
were incubated for 3 hours with the indicated agonists. Apical expression of PAR1
was analyzed in a cell-surface ELISA using monoclonal anti-PAR1 antibodies
SPAN11, ATAP2, and WEDE15. Results are shown relative to control (means  SEM,
n  9, **P  .005).
Figure 1. Protective signaling by APC in the presence of thrombin. EA.hy926
cells in a dual-chamber system were incubated for 3 hours with the indicated agonists
in the top chamber followed by analysis of permeability. Means plus or minus SEM
with n  5 (A) and 10 (B). **P  .005.
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immunofluorescence microscopy demonstrated that the anti-PAR1
antibodies under conditions used for the ELISA indeed only bind to
cell surface PAR1 and do not detect intracellular pools (Figure
S1A, available on the Blood website; see the Supplemental
Materials link at the top of the online article). Thrombin dose–
dependently down-regulated binding of 3 monoclonal antibodies
that were raised against the N-terminal exodomain of human PAR1,
ie, SPAN11, ATAP2, and WEDE1520,21 (Figure 2), consistent with
the expected cleavage and internalization of PAR1.27 APC incuba-
tion strongly decreased binding of the cleavage-sensitive SPAN11,
indicating that APC reduces surface availability of native, un-
cleaved PAR1. Binding of the non–cleavage-sensitive WEDE15,
which binds to an epitope downstream from the Arg41 cleavage
site in PAR1’s N-terminal exodomain, was not affected by APC,
indicating that levels of total surface PAR1 remain constant. These
data demonstrate for the first time directly that incubation with
APC leads to cleavage of endogenous endothelial cell PAR1. APC
down-regulated ATAP2 binding although ATAP2 also binds to an
epitope downstream from the Arg41 cleavage site and is regarded
as a non–cleavage-sensitive anti-PAR1. This unexpected result
indicates that the APC-cleaved PAR1 is detected on the cell surface
by WEDE15 but not by ATAP2. ATAP2 recognizes PAR1’s
Leu44-Arg46 amino acid stretch while WEDE15 binds further
downstream at Phe55-Glu60.20,21 Previous data indicate that APC
can only directly cleave PAR1’s N-terminal exodomain at Arg41.28
Incubation with APC might lead to activation of other cellular
proteases that in turn might cleave PAR1 at additional sites and
cause shedding of the ATAP2 but not the WEDE15 epitope.
However, effects of APC on ATAP2 staining were found to be
comparable in native cells and cells that have been fixed before
agonist incubation (Figure 3A), suggesting that loss of ATAP2
binding is mediated by a conformational change after cleavage.
Western blotting of biotinylated cell-surface proteins was used to
test whether the ATAP2 epitope can be detected in denatured
cleaved PAR1 after APC incubation. The surface biotinylation–
based assay does not detect intracellular PAR1, as shown in control
experiments (Figure S1B). PAR1 migrated as an elongated immu-
noreactive band as reported earlier and prolonged incubation with
APC led to a cleavage product at the expected smaller size.28,29
Both WEDE15 and ATAP2 anti-PAR1 similarly detected native
and cleaved PAR1 (Figure 3B). The ATAP2 epitope in APC-
cleaved PAR1 is thus not shed or degraded and becomes available
for ATAP2 binding in denatured PAR1. In conclusion, WEDE15 is
a non–cleavage-sensitive antibody and detects total PAR1 in both
native (ELISA) and denaturing (Western blotting) conditions.
ATAP2 does also bind to cleaved and uncleaved denatured PAR1;
however, it is conformation sensitive and does not bind to the
cleaved PAR1 in the cell-surface immunoassay.
PAR1 cleavage by APC
Given that ATAP2 is commercially available and sensitive to the
conformational change upon cleavage of PAR1 we used this
antibody to assess cleavage of endogenously expressed PAR1.
Results were confirmed using SPAN11 as indicated below. APC
and thrombin down-regulated the binding of ATAP2 in a time
dependent manner and 20 nM of APC was similarly efficient as
40 pM thrombin (Figure 4A). A proteolytically inactive recombi-
nant APC variant with an S3A substitution at the active center did
not affect ATAP2 binding (Figure 4B). As expected, PAR1 cleavage
by APC was completely inhibited in the presence of an antibody
against EPCR that blocks APC binding to EPCR (Figure 4C). In
contrast, APC significantly down-regulated ATAP2 binding in the
presence of nonblocking anti-EPCR, albeit to a lesser extent than in
the absence of antibody. A possible explanation for the effect of
nonblocking anti-EPCR might be that the antibody leads to
clustering and internalization of EPCR during the 3-hour experi-
ment. Down-regulation of ATAP2 binding in response to APC thus
requires both APC’s proteolytic activity and APC binding to EPCR.
For all subsequent experiments analyzing effects of exogenously
added APC a concentration of 20 nM was used and agonist
Figure 3. ATAP2 does not detect PAR1’s active conformation generated after
scissile bond cleavage. (A) ATAP2 binding was quantified by cell-surface ELISA
after incubation for 3 hours with the indicated agonists in cells before and after fixation
with paraformaldehyde (PFA). PMA indicates phorbol myristate acetate (0.1 g/mL).
Means plus or minus SEM are shown (n  12). (B) Cells were incubated for 3 hours
with control or APC (20 nM) and biotinylated surface proteins were analyzed by
Western blotting with WEDE15 or ATAP2 as indicated. A representative experiment of
3 is shown.
Figure 4. APC down-regulates ATAP2 binding dependent on proteo-
lytic activity and EPCR binding. (A) ATAP2 binding was quantified by
ELISA after incubation with the indicated agonists in time course
experiments. (B) Cells were incubated for 3 hours with the indicated
concentrations of recombinant wild-type APC or proteolytically inactive
APC S360A and ATAP2 binding was quantified. (C) Cells were preincu-
bated (10 minutes) in the absence and presence of nonblocking
(RCR-92) or blocking (RCR-252) anti-EPCR (25 g/mL) followed by
3 hours of incubation with the indicated agonists and quantification of
ATAP2 binding. Means plus or minus SEM are shown (n  6 in panels
A,C; n  9 in panel B. **P  .005).
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incubation was for 3 hours to obtain significant EPCR-dependent
cleavage of PAR1.
APC can mediate additional PAR1 cleavage even if thrombin is
also present
When APC was coincubated with thrombin an additional loss of
ATAP2 binding was detected (Figure 5A). APC also caused an
additional loss of ATAP2 binding in cells that were fixed before
agonist incubation consistent with direct effects of APC on PAR1.
Endothelial cells have intracellular pools of PAR1 and previous
studies have shown that both native and cleaved PAR1 are
translocated to the cell surface upon agonist treatment.20,25 As
shown in Figure 5B, the cell surface was repopulated with PAR1
after a high-dose thrombin challenge with similar kinetics in the
EA.hy926 cell line as described previously for HUVECs. Brefeldin
A, an inhibitor of vesicle trafficking that blocks exocytosis but not
internalization of membrane proteins,30 prevented repopulation of
the cell surface with ATAP2 binding sites (Figure 5B). When
surface repopulation was blocked with brefeldin A, APC caused a
significant additional loss of ATAP2 binding in the presence of up
to 360 pM thrombin (Figure 5C). Similar results were obtained
using the cleavage-sensitive antibody SPAN11 (not shown). We
have previously shown that the endogenous PC activation pathway
is mechanistically linked to efficient PAR1-dependent protective
signaling.23 Consistent with these results, when cells were incu-
bated with thrombin in the presence of PC zymogen, ATAP2
binding (and SPAN11 binding; not shown) was further decreased
even when only low nM APC was generated (Figure 5D).
APC-cleaved PAR1 is inefficiently removed from the
cell surface
Given that EA.hy926 cells can rapidly externalize PAR1 to the cell
surface after agonist treatment (Figure 5B), our finding that APC
does not affect WEDE15 binding (Figure 2) could be explained by
efficient repopulation of the cell surface with cleaved and/or
uncleaved PAR1 from intracellular pools. However, APC did not
down-regulate WEDE15 staining even in the presence of brefeldin
A (Figure 6A), demonstrating that, in contrast to thrombin-cleaved
PAR1, APC-cleaved PAR1 is retained on the cell surface. The
cleaved PAR1 present on the cell surface after APC incubation was
still retained after a subsequent incubation with high-dose thrombin
(Figure 6B).
These results raise the possibility that APC-cleaved PAR1 might
accumulate on the cell surface even in the presence of thrombin.
When ATAP2 (detects only uncleaved PAR1) and WEDE15
(detects both cleaved and uncleaved PAR1) binding was analyzed
in parallel experiments after incubation with increasing concentra-
tions of thrombin alone, staining with both antibodies was almost
identical (Figure 7A). This finding indicates that no detectable
cleaved PAR1 is retained on the cell surface upon thrombin
incubation. If the cells were coincubated with APC, ATAP2 binding
was further decreased, consistent with additional cleavage of PAR1
by APC in the presence of thrombin. In contrast, coincubation with
APC led to enhanced WEDE15 binding, demonstrating that total
Figure 5. Both exogenous and endogenously generated APC support addi-
tional PAR1 cleavage in the presence of thrombin. (A) Nonfixed or PFA-fixed cells
were incubated for 3 hours with different concentrations of thrombin in the absence or
presence of APC as indicated, followed by analysis of ATAP2 binding. (B) Cells were
incubated with 20 nM thrombin for 10 minutes followed by quenching of the protease
with 50 nM hirudin. Recovery of ATAP2 binding upon incubation at 37°C over 3 hours
is plotted. Where indicated, the cells were PFA-fixed or pretreated with brefeldin A
(1 M, 10 minutes) before the addition of thrombin. A representative experiment (of 3)
is shown. (C) Brefeldin A–treated cells were incubated for 3 hours as indicated
followed by analysis of ATAP2 binding. (D) Nonfixed cells were incubated with the
indicated concentrations of thrombin in the absence or presence of 80 nM PC. After
3 hours the APC concentration in the conditioned medium was determined by
chromogenic assay and ATAP2 binding was analyzed. Means plus or minus SEM are
shown (n  9 in panels A,C,D. *P  .05, **P  .005).
Figure 6. APC cleaved PAR1 remains on the cell surface. (A) Cells were incubated
with agonists for 3 hours in the absence or presence of brefeldin A followed by
analysis of ATAP2 or WEDE15 binding by surface ELISA as indicated. Means plus or
minus SEM are shown (n  9). (B) Cells were incubated for 3.5 hours with 100 pM
hirudin without or with additional 20 nM of APC. For the final 30 minutes of incubation
either control or 500 pM of thrombin was added and cell surface–expressed PAR1
was quantified by analysis of ATAP2 and WEDE15 binding. Means plus or minus
SEM are shown (n  9, **P  .005 comparing results without and with thrombin for
final 30 minutes).
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(cleaved and uncleaved) PAR1 is increased. Because the differen-
tial between WEDE15 and ATAP2 staining corresponds to the
amount of cleaved PAR1 these findings show that treatment with
APC results in the retention of cleaved PAR1 on the cell surface in
the absence as well as in the presence of up to 1 nM thrombin.
Analysis of biotinylated cell-surface proteins by Western blotting
confirmed that coincubation with APC reproducibly led to higher
levels of PAR1 on the cell surface compared with thrombin alone
(Figure 7B). To test whether similar results are also obtained in
inflammatory cytokine-perturbed endothelial cells, we analyzed
cleavage and surface retention of PAR1 in response to incubation
with APC and thrombin in cells that were pretreated with a high
concentration of tumor necrosis factor- (TNF; Figure 7C).
TNF reduced the amount of surface-exposed native PAR1 and
PAR1 cleavage by APC was found to be slightly less efficient in
TNF-induced cells most likely because of decreased EPCR
expression. However, APC still supported significant PAR1
cleavage in both the absence and presence of thrombin and the
APC-cleaved PAR1 was surface retained, entirely consistent
with our results in quiescent cells. Although the differences
were relatively small in TNF-pretreated cells, the data show
that APC leads to a unique population of cleaved PAR1 on the
cell surface that might mediate APC’s beneficial effects in
systemic inflammation.
Discussion
In sepsis the efficient PAR1 activator thrombin is generated, and
therefore the question how any beneficial effects of APC can be
PAR1 mediated is at the root of the current controversy. So far it
was difficult to explain how APC can mediate any effects through
PAR1 because thrombin is much more efficient in cleaving this
receptor. Our data directly demonstrate for the first time that APC
can cleave endogenous PAR1 on the surface of human endothelial
cells, corroborating conclusions from studies using overexpressed
tagged PAR1 constructs16 or cleavage blocking antibodies against
PAR1.6 Exogenous and endogenously generated APC can mediate
both endothelial barrier protective signaling and additional cleav-
age of endogenous PAR1 on the endothelial cell surface even in the
presence of up to 1 nM of thrombin. The absence of detectable
additional cleavage of epitope tagged PAR1 by generated APC in a
previous study16 could be explained by preferential cleavage of the
overexpressed receptor by thrombin that binds directly to PAR1
and does not require a coreceptor.26 Our finding that APC has no
detectable additional effect on PAR1 cleavage in the presence of
high thrombin concentrations ( 1 nM) argues that any distinct
PAR1 population that can only be cleaved by APC but not by
thrombin would have to be very small. Consistent with the findings
by Bae et al26 we propose that there is a PAR1 population that is
colocalized with EPCR and that is cleaved by APC. Even though
thrombin can also cleave this PAR1 population, cleavage by APC is
efficient enough to lead to significant additional cleavage at up to
high-picomolar thrombin concentrations.
Whereas thrombin-cleaved PAR1 is rapidly internalized and
degraded,27 our data show that APC-activated PAR1 remains on the
cell surface and accumulates upon prolonged incubation even when
thrombin is present. It has been recently established that down-
stream G-protein coupling of PAR1 differs for specific agonists.31
Therefore, it is conceivable that even though thrombin and APC
activate PAR1 by cleaving the same scissile bond28 differences in
the interaction of the tethered ligand with PAR1 could lead to the
activation of distinct downstream signaling pathways and to unique
biologic responses, including distinct trafficking of thrombin- and
APC-cleaved PAR1. Such differences might also explain the
finding that thrombin and APC can have distinct effects on gene
expression through PAR1 signaling in cytokine-perturbed endothe-
lial cells.8 Our previous results demonstrate that low (40 pM) but
not high thrombin concentrations can induce endothelial barrier
protection similar to APC,11 suggesting that differences in the
PAR1 cleavage rate translate into distinct downstream signaling.
Our present results that APC can mediate protective effects in the
presence of thrombin concentrations much higher than 40 pM
indicate that differences in the cleavage rate alone cannot explain
Figure 7. APC-cleaved PAR1 is retained on the cell surface even in the presence
of thrombin. (A) Nonfixed cells were incubated for 3 hours with the indicated
agonists and cell surface–expressed PAR1 was quantified by analysis of ATAP2 and
WEDE15 binding. (B) After incubation with the indicated agonists for 3 hours, surface
proteins were biotinylated and isolated with streptavidin agarose. PAR1 was detected
by Western blotting using anti-PAR1 WEDE15. A representative experiment is shown
in the top panel. Optical density of immunoreactive bands was measured in
3 independent experiments and means plus or minus SEM are shown in the bottom
panel. Coincubation with APC led to detection of more surface PAR1 at all thrombin
concentrations, a finding that was borderline significant at lower thrombin concentra-
tions but significant at 360 pM thrombin. (C) As indicated, cells were induced with
TNF for 2 hours and thrombin and/or APC added for an additional 3 hours followed
by quantification of ATAP2 and WEDE15 binding. Means plus or minus SEM are
shown in panels A,C (n  15 in panel A and 7 in panel C, *P  .05, **P  .005,
comparing results without and with APC in panel A).
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all the findings. One possibility is that APC binding to EPCR leads
to distinct signaling of the colocalized PAR1.32 Although extensive
research will be required to elucidate molecular details of the
downstream signaling pathways and to establish that the surface-
retained PAR1 indeed mediates protective APC effects in the
presence of thrombin, our results provide conceptually novel
insight into the paradoxical condition that the 2 key coagulation
proteases thrombin and APC, linked by a negative feedback loop,
can mediate opposite effects on endothelial biology through the
same receptor PAR1.
Our finding that cellular trafficking of thrombin- and APC-
cleaved PAR1 is distinct suggests how receptor signaling by a very
inefficient protease can be relevant in the presence of the much
stronger agonist thrombin. Because of the irreversibility of proteo-
lytic activation PAR1 signaling must be regulated through mecha-
nisms such as receptor trafficking.27 Although the rate of thrombin-
PAR1 cleavage at any given point in time might be much higher
than the rate of APC-PAR1 cleavage, the thrombin-cleaved recep-
tor is rapidly internalized and degraded whereas the APC-cleaved
receptor accumulates on the surface and can potentially mediate
relevant signaling in the presence of thrombin. This illustrates how
the efficiency of induction of a specific biologic response does not
necessarily correlate with efficiency of cleavage. This concept
cannot only explain our finding that APC enhances endothelial
barrier integrity in the presence of thrombin, but it might help to
clarify the complex roles of PAR1 in vivo. PAR1 deficiency did not
affect survival in mouse models of endotoxemia,33,34 even though
PAR1 has well-established proinflammatory effects in other mod-
els, such as glomerulonephritis, inflammatory bowel disease, or
ischemia-reperfusion injury.35-37 This argues that any detrimental
effects of PAR1 deficiency in systemic inflammation might be
offset by the absence of proinflammatory PAR1 signaling. Very
recent results indeed support the conclusion that PAR1 has such
dual roles during different stages of the inflammatory response in
mouse models of severe sepsis.38,39 These findings suggest that
PAR1 mediates protective signaling by the PC pathway in vivo
under conditions where thrombin is also present. Our in vitro data
suggest that relevant protective PAR1 signaling by the PC pathway
might be possible in the presence of up to high-picomolar or
low-nanomolar thrombin. PAR1 is activated with half maximal
efficiency by a concentration of only approximately 50 pM
thrombin14 and thrombin activity in vivo is rigorously controlled to
prevent excessive platelet activation/fibrin formation. Although it
is not known what the thrombin concentration in the endothelial
cell microenvironment under conditions of inflammatory stress
might be, data from Dr Coughlin’s laboratory elegantly demon-
strate that thrombin likely operates close to threshold levels: In
murine platelets PAR4 cleavage is required for thrombin signaling
and PAR3 acts as a nonsignaling cofactor that recruits thrombin and
decreases the concentration required for half maximal signaling
between 6- and 15-fold.40 However, PAR3- and PAR4-deficient
mice showed similar degrees of protection in thrombosis models,
indicating that an approximately 10-fold decrease in platelet
responsiveness to thrombin has the same effect as complete
unresponsiveness.41,42 Based on these findings, we expect that the
range of thrombin concentrations where we obtained protective
signaling and surface retention of APC-cleaved PAR1 is of
physiologic relevance.
In conclusion, our results help explain how using a single
receptor cell can sense proteolytic activity of thrombin and APC
independently, and they support the concept that PAR1-dependent
signaling might contribute to protective effects of APC in sepsis.
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